Raj. HC: No Jurisdiction on DRT to Modify Settlement Terms in Appli. Filed after Disposal of Matter  ||  Kar. HC: Second Petition u/s 482 of CrPC Not Maintainable Unless Founded Upon Change in Circumstance  ||  Centre to Delhi HC: In Process of Framing Rules Under New Online Gaming Act  ||  Karnataka HC: Compelling DNA Tests without Imminent Need becomes Violative of Article 21  ||  SC: TET Qualification Mandatory for Teachers in Minority Institutions  ||  SC: Agreement to Sell Does Not Confer a Valid Title on a Party as it is Not a Deed of Conveyance  ||  SC Criticizes NGT for Outsourcing its Responsibilities to External Committees  ||  SC: No Culprit Should Manage an Acquittal on the Basis of Unreasonable Doubts  ||  Delhi High Court Dismisses Bail Pleas of Umar Khalid and Other Accused in 2020 Delhi Riots Case  ||  Supreme Court Judges Launch Schemes for Human -Wildlife Conflict    

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK   MERCK   PATENT   DIABETES  

Share :        

Disclaimer | Copyright 2025 - All Rights Reserved